RSS

The Institute for OneWorld Health: Not-for-profit Drugmaking

By: Jennifer VilagaTue Nov 25, 2008 at 8:30 PM
Founder and Board Chair: Victoria Hale

Victoria Hale



Related Content


Ten years ago, Victoria Hale wrote a manifesto targeting five diseases in need of drug development and turned it into a business plan for the first pharmaceutical not-for-profit in the United States. Today, her organization, the Institute for OneWorld Health, is on the verge of proving that its no-profit/no-loss model can work. Its first drug, paromomycin -- a treatment for visceral leishmaniasis, an illness spread by sand flies that mostly afflicts the poorest of the poor -- is months from completing its final stage of clinical trials. Up next: malaria. Backed by a $42.6 million grant from the Gates Foundation, OneWorld Health aims to create and market semisynthetic artemisinin, a key malaria-fighting ingredient that's in short supply.

Topics:

Ethonomics, artemisinin, Institute for OneWorld Health, visceral leishmaniasis, Victoria Hale, social enterprises of the year, pharmaceutical not-for-profit, Gates Foundation, paromomycin, malaria, Victoria Hale, Malaria, Health and Fitness, Medicine, Contagious and Infectious Diseases

From Issue 131 | December 2008

Sign in or register to comment.
or

Recent Comments | 2 Total

September 20, 2009 at 2:47pm by john smith

great article. its Great to see woman doing something great

Honda Accessories

November 17, 2009 at 8:44pm by Arthur Chachuna

What a worthy course. I really hope you guys will succeed!

--
Arthur,
best bank rates | work positions